Circassia Pharmaceuticals Plc (CIR):企業の財務・戦略的SWOT分析

◆英語タイトル:Circassia Pharmaceuticals Plc (CIR) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C4813
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Circassia Pharmaceuticals Plc (CIR) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease. The company had several inhaled medicines in pipeline intended for the treatment chronic obstructive pulmonary disease (COPD), which include single and combination dose products. The company offers its products to COPD and asthma specialists in the US, the UK, Germany and other countries through its network of partners. Circassia is headquartered in Oxford, England, the UK.

Circassia Pharmaceuticals Plc Key Recent Developments

Apr 24,2018: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2017
Feb 13,2018: Circassia Announces Changes to its Board of Directors
Nov 29,2017: Circassia Welcomes New NICE Guidelines Recommending Use of FeNO Testing in Asthma Diagnosis
Sep 27,2017: Circassia Pharmaceuticals: Interim Results for the Six Months Ended 30 June 2017
Apr 25,2017: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Circassia Pharmaceuticals Plc – Key Facts 6
Circassia Pharmaceuticals Plc – Key Employees 7
Circassia Pharmaceuticals Plc – Key Employee Biographies 8
Circassia Pharmaceuticals Plc – Major Products and Services 9
Circassia Pharmaceuticals Plc – History 10
Circassia Pharmaceuticals Plc – Company Statement 11
Circassia Pharmaceuticals Plc – Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Company Overview 14
Circassia Pharmaceuticals Plc – Business Description 15
Business Segment: Niox Segment 15
Overview 15
Performance 15
Business Segment: Respiratory segment 15
Overview 15
Performance 15
Business Segment: US AZ collaboration 15
Overview 15
Performance 15
Geographical Segment: Asia Pacific 16
Performance 16
Geographical Segment: EU 16
Performance 16
Geographical Segment: Rest of World 16
Performance 16
Geographical Segment: US 16
Performance 16
R&D Overview 16
Circassia Pharmaceuticals Plc – SWOT Analysis 17
SWOT Analysis – Overview 17
Circassia Pharmaceuticals Plc – Strengths 17
Circassia Pharmaceuticals Plc – Weaknesses 18
Circassia Pharmaceuticals Plc – Opportunities 19
Circassia Pharmaceuticals Plc – Threats 20
Circassia Pharmaceuticals Plc – Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios – Capital Market Ratios 22
Financial Ratios – Annual Ratios 23
Performance Chart 25
Financial Performance 25
Financial Ratios – Interim Ratios 26
Financial Ratios – Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Circassia Pharmaceuticals Plc, Recent Deals Summary 30
Section 5 – Company’s Recent Developments 31
Apr 24, 2018: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2017 31
Feb 13, 2018: Circassia Announces Changes to its Board of Directors 32
Nov 29, 2017: Circassia Welcomes New NICE Guidelines Recommending Use of FeNO Testing in Asthma Diagnosis 33
Sep 27, 2017: Circassia Pharmaceuticals: Interim Results for the Six Months Ended 30 June 2017 34
Apr 25, 2017: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2016 35
Apr 25, 2017: Circassia Announces Non-Executive Director Retirements 36
Section 6 – Appendix 37
Methodology 37
Ratio Definitions 37
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Circassia Pharmaceuticals Plc, Key Facts 6
Circassia Pharmaceuticals Plc, Key Employees 7
Circassia Pharmaceuticals Plc, Key Employee Biographies 8
Circassia Pharmaceuticals Plc, Major Products and Services 9
Circassia Pharmaceuticals Plc, History 10
Circassia Pharmaceuticals Plc, Subsidiaries 13
Circassia Pharmaceuticals Plc, Key Competitors 21
Circassia Pharmaceuticals Plc, Ratios based on current share price 22
Circassia Pharmaceuticals Plc, Annual Ratios 23
Circassia Pharmaceuticals Plc, Annual Ratios (Cont...1) 24
Circassia Pharmaceuticals Plc, Interim Ratios 26
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Circassia Pharmaceuticals Plc, Recent Deals Summary 30
Currency Codes 37
Capital Market Ratios 37
Equity Ratios 38
Profitability Ratios 38
Cost Ratios 39
Liquidity Ratios 39
Leverage Ratios 40
Efficiency Ratios 40

List of Figures
Circassia Pharmaceuticals Plc, Performance Chart (2013 - 2017) 25
Circassia Pharmaceuticals Plc, Ratio Charts 27
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

★海外企業調査レポート[Circassia Pharmaceuticals Plc (CIR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • OpenWay Group:企業の戦略的SWOT分析
    OpenWay Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Vossloh AG:企業のM&A・事業提携・投資動向
    Vossloh AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vossloh AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Marenica Energy Ltd (MEY):企業の財務・戦略的SWOT分析
    Summary Marenica Energy Ltd (MEY) is a mining and mineral resource exploration and development company that acquires, identifies, develops, and explores for lead, silver, zinc, copper, uranium and gold mineral properties in Australia. The company develops and operates uranium project using conventio …
  • Aptitude Medical Systems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aptitude Medical Systems Inc (Aptitude Medical) is a developer of dynamic proteins, lipids, sugars and metabolites. The company's target range comprises nonimmunogenic proteins, peptides, toxins, glycans, drugs, metabolites and small epitopes. Its integrated suite of proprietary technologies …
  • Virgin Australia Holdings Limited:企業のM&A・事業提携・投資動向
    Virgin Australia Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Virgin Australia Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • CooperVision Inc:製品パイプライン分析
    Summary CooperVision Inc (CooperVision), a subsidiary of The Cooper Companies Inc, designs and manufactures soft contact lenses. It manufactures a wide array of monthly, two-week and daily disposable contact lenses. CooperVision helps overcome various vision challenges such as astigmatism and presby …
  • Gordon Ramsay Holdings Limited:企業の戦略・SWOT・財務情報
    Gordon Ramsay Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Gordon Ramsay Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Crystal Pharmatech Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Crystal Pharmatech Co Ltd (Crystal Pharmatech) is a contract research organization that conducts research on engineering and materials science for drug development. The organization offers pharmaceutical solid-state research services such as solid form screening and selection, single crystal …
  • The Royal Bank Of Scotland Group Plc
    The Royal Bank Of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report Summary The Royal Bank Of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • NBE-Therapeutics AG:製薬・医療:M&Aディール及び事業提携情報
    Summary NBE-Therapeutics AG (NBE-Therapeutics) is a biotechnology company that focuses on the development of antibody drug conjugates (ADC) to improve the treatment of cancer. ADCs act against cancer cells via tumor-specific antibodies and deliver powerful cellular toxins to such cancer cells. The c …
  • GenMark Diagnostics Inc (GNMK):企業の財務・戦略的SWOT分析
    Summary GenMark Diagnostics Inc (GenMark) is a medical device company that provides clinical testing systems. The company provides products such as XT-8 systems and ePlex systems. It offers pipeline products such as eSensor 2C 19 genotyping test, eSensor HCV genotyping test, eSensor HCVg direct test …
  • Fisher & Paykel Appliances Holdings Limited:企業の戦略的SWOT分析
    Fisher & Paykel Appliances Holdings Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Luitpold Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Luitpold Pharmaceuticals Inc (Luitpold), a subsidiary of Daiichi Sankyo Company Ltd is a manufacturer and marketer of drugs and medical devices. The company provides injectable parenteral medications that are used in pharmacy admixtures and nutrient solutions, antidotes, critical care drugs, …
  • ONEOK, Inc.:企業の戦略・SWOT・財務情報
    ONEOK, Inc. - Strategy, SWOT and Corporate Finance Report Summary ONEOK, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Auswide Bank Ltd (ABA):企業の財務・戦略的SWOT分析
    Auswide Bank Ltd (ABA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Booz Allen Hamilton Holding Corporation:企業の戦略・SWOT・財務情報
    Booz Allen Hamilton Holding Corporation - Strategy, SWOT and Corporate Finance Report Summary Booz Allen Hamilton Holding Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • MediPlast AB-医療機器分野:企業M&A・提携分析
    Summary MediPlast AB (MediPlast) is a medical device company that offers surgery equipment. The company manufactures, markets, distributes, and sells medical technical equipment and disposable products. Its products include swabs and balls, conforming and support bandages, cohesive bandages, compres …
  • Centene Corporation:企業の戦略・SWOT・財務情報
    Centene Corporation - Strategy, SWOT and Corporate Finance Report Summary Centene Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • API Group plc:企業の戦略・SWOT・財務情報
    API Group plc - Strategy, SWOT and Corporate Finance Report Summary API Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • HSH Nordbank Private Banking:企業の戦略・SWOT・財務情報
    HSH Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report Summary HSH Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆